Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24329884 | 0.87 | MEN1 (0.51) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL21320757 | 0.82 | ALDH1A1 (0.46) | MEN1KMT2ATP53MAPTHPGD | |
| SCHEMBL829880 | 0.81 | MEN1 (0.62) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL3435026 | 0.81 | MEN1 (0.62) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL419918 | 0.80 | PIK3CA (0.42) | MEN1KMT2ATP53MAPTPIK3CD | |
| SCHEMBL19936511 | 0.79 | SMN1; SMN2 (0.62) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL8969364 | 0.79 | ACHE (0.69) | MEN1KMT2AMAPTLMNAHPGD | |
| SCHEMBL6920428 | 0.79 | MEN1 (0.63) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL3435382 | 0.78 | MEN1 (0.59) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL2050608 | 0.78 | MEN1 (0.66) | MEN1KMT2ALMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | MEN1 389/4885KMT2A 880/4885TP53 4820/4885 |
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC5R | MEN1 200/4885KMT2A 636/4885TP53 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.